Les Funtleyder, Esquared Asset Management, discusses Carl Icahn's large position in Allergan and investing in biotech. » Read More
Martin Shkreli's tweet endorsement of the Republican nominee comes as he fights criminal fraud charges.
A gene therapy from Spark Therapeutics is offering patients with a rare genetic retinal disease that causes blindness some hope.
New medicines are increasingly targeting the genetic drivers of disease. But what if medicine could go further and correct the genetic defect itself?
Valeant received a joint takeover offer from Japan's Takeda and TPG Capital this spring that the Canadian drugmaker rejected, according to a source.
Scientists are working on a new treatment for depression and PTSD: deep-brain stimulation.
When we think about taking medicines, we imagine popping a pill, or receiving a shot. But a new approach would leverage the body's electrical signals.
The Defense Department is helping to develop prosthetics that harness what we've learned about the brain's functions.
Shares of Sarepta Therapeutics rose more than 20 percent.
Imagine implanting electrodes in the hippocampus to help brain-injured patients process memories. That's what the Defense Department is attempting.
With funding from DARPA, scientists hope to develop brain implants that can help restore memory for individuals with brain damage.
Dennis Gartman, founder, editor & publisher of The Gartman Letter, comments on Monsanto's decision to reject the Bayer acquisition proposal.
Neil Dwane, global strategist at Allianz Global Investors, says many Bayer investors will view the deal negatively as they won't own Monsanto.
The pharmaceutical company Bayer has announced plans to acquire American biotech company Monsanto, making an all cash offer of $122 per share.
Robert Mulroy, Merrimack Pharmaceuticals CEO, discusses the company's oncology pipeline and clinical basket trial.
The blood-testing start up decides to withdraw two years of test results.
IBM's World Community Grid links volunteers' personal computers and mobile devices to form a supercomputer for disease research.
German drug and chemicals giant Bayer has made an unsolicited takeover offer for Monsanto, the world's biggest seed company.
A rare and previously unknown variation in some people's genes substantially reduces their heart attack risk, the Icelandic researchers said.
CNBC's Meg Tirrell reports all the latest news in biotech. The Fast Money panel weighs in.
Citron's Andrew Left says he does not think Valeant shares will trade above $60 anytime soon.
Get the best of CNBC in your inbox